Headquartered in Cheshire, Connecticut, Alexion employs more than 1,100 people around the world.
In addition to our corporate headquarters, Alexion’s facilities include a global manufacturing
plant in Smithfield, Rhode Island; the Alexion Translational Medicine Group, in Cambridge,
Massachusetts; EMEA (Europe, Middle East & Africa) regional headquarters in Lausanne, Switzerland;
a European shared service center in Paris, France; distribution and sales operations in major
markets throughout Europe, and new operations in Tokyo, Japan, Sydney, Australia, São Paulo,
Brazil, Ontario, Canada and other countries. The company is also expanding its reach in Latin America, the Middle East and Africa.
Alexion’s global presence reflects the approval of Soliris for the treatment of patients with PNH in more than 40 countries,
as well as the approval of Soliris for the treatment of aHUS in the United States and the European Union.
The company is working toward seeking regulatory approval for both indications in additional regions.